Skip to content

Effects of expression of inflammatory cytokines and heat shock protein 70 on sevoflurane for preeclampsia maternal

Effects of expression of inflammatory cytokines and heat shock protein 70 on sevoflurane for preeclampsia maternal

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014571
Enrollment
Unknown
Registered
2018-01-22
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

Group SP:sevoflurance
Group SN:sevoflurance

Sponsors

Guangdong Women and Children Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age between 22 and 35 years; Gestational age 30 to 40 weeks;Preeclampsia women 20 cases. Diagnosis and classification standard according to the journal of obstetrics and gynecology (eighth edition) [to admit effusion, pregnancy-induced hypertension disease. Xie Xing, obstetrics and gynecology. 8 edition. Beijing: people's medical publishing house, 2013; 92:101]. Take over the same period of blood pressure normal pregnancy women group, 6 cases of normal pregnancy age 24 to 35 years old; Gestational age 33-40 weeks. Two groups are based on single pregnancies, all women are not intentional, liver, kidney, thyroid disease, and blood, and without diabetes, chronic hypertension, rheumatism, rheumatoid disease, and history of autoimmune diseases such as systemic lupus erythematosus (sle), without premature rupture of membranes, preterm birth and signs of infection.

Exclusion criteria

Exclusion criteria: Heart, liver, kidney, thyroid disease and blood disease, diabetes, chronic hypertension, rheumatism, rheumatoid disease, and history of autoimmune diseases such as systemic lupus erythematosus (sle), premature rupture of membranes, preterm labor, and signs of infection.

Design outcomes

Primary

MeasureTime frame
IL-6;HSP70;

Countries

China

Contacts

Public ContactJia Jie

Guangdong Women and Children Hospital

jiajie8712@sina.com+86 13828459960

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026